Literature DB >> 8425485

Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo.

L C Huang1, M C Fonteles, D B Houston, C Zhang, J Larner.   

Abstract

Two insulin mediators, inositol phosphoglycans, were isolated from bovine liver by methods previously developed for rat liver, i.e. chromatography on an AG 1 x 8 ion exchange column and selective elution with HCl at pH 2.0 and 1.3. The pH 2.0 mediator containing D-chiroinositol stimulated pyruvate dehydrogenase phosphatase, whereas the pH 1.3 mediator containing myo-inositol inhibited cAMP-dependent protein kinase. Each mediator was further purified by thin layer and Bio-Gel P4 column chromatography and injected ip into normal fed rats together with [U-14C]glucose. After 2.5 h, diaphragms were removed, and glycogen isolated. Insulin mediators, like insulin, stimulated [U-14C]glucose incorporation into glycogen by 150-160% in a dose-dependent manner in the nanomolar range. Mediators injected iv in the nanomolar range into low dose streptozotocin-diabetic rats decreased plasma glucose 30-45% in 30-60 min, with a return to basal concentrations after 150-180 min. These in vivo insulin-like effects of mediator were observed without changes in serum insulin concentrations. The pH 2.0 mediator was 50-100 times more active (per nmol organic phosphate) than the pH 1.3 mediator in the ip diaphragm glycogenesis assay. Mediator effects on diaphragm were completely blocked by preincubation with an immunopurified inositol phosphoglycan antibody. Both mediators were equally active iv in lowering plasma glucose (per nmol inositol) at concentrations comparable to those of insulin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425485     DOI: 10.1210/endo.132.2.8425485

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

1.  Inositols prevent and reverse endothelial dysfunction in diabetic rat and rabbit vasculature metabolically and by scavenging superoxide.

Authors:  N R F Nascimento; L M A Lessa; M R Kerntopf; C M Sousa; R S Alves; M G R Queiroz; J Price; D B Heimark; J Larner; X Du; M Brownlee; A Gow; C Davis; M C Fonteles
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-22       Impact factor: 11.205

2.  Infusion of pH 2.0 D-chiro-inositol glycan insulin putative mediator normalizes plasma glucose in streptozotocin diabetic rats at a dose equivalent to insulin without inducing hypoglycaemia.

Authors:  M C Fonteles; L C Huang; J Larner
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

3.  Inositol, glycogen, insulin, and six nobelists.

Authors:  Joseph Larner
Journal:  J Biol Chem       Date:  2013-03-20       Impact factor: 5.157

Review 4.  Diabetes and the role of inositol-containing lipids in insulin signaling.

Authors:  D R Jones; I Varela-Nieto
Journal:  Mol Med       Date:  1999-08       Impact factor: 6.354

Review 5.  D-chiro-inositol glycans in insulin signaling and insulin resistance.

Authors:  Joseph Larner; David L Brautigan; Michael O Thorner
Journal:  Mol Med       Date:  2010-08-27       Impact factor: 6.354

6.  Insulin-like effect of pinitol.

Authors:  S H Bates; R B Jones; C J Bailey
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

7.  Soy pinitol acts partly as an insulin sensitizer or insulin mediator in 3T3-L1 preadipocytes.

Authors:  Gyeong-Min Do; Myung-Sook Choi; Hye-Jin Kim; Myung-Nam Woo; Mi-Kyung Lee; Seon-Min Jeon
Journal:  Genes Nutr       Date:  2008-02       Impact factor: 5.523

8.  High Doses of D-Chiro-Inositol Alone Induce a PCO-Like Syndrome and Other Alterations in Mouse Ovaries.

Authors:  Arturo Bevilacqua; Jessica Dragotto; Micaela Lucarelli; Giovanna Di Emidio; Giovanni Monastra; Carla Tatone
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

9.  CONCERN: Does ovary need D-chiro-inositol?

Authors:  Rosalbino Isabella; Emanuela Raffone
Journal:  J Ovarian Res       Date:  2012-05-15       Impact factor: 4.234

10.  Experimental model proposed to deduce pharmacological evidence of the beta-cell neogenesis activity of Argyrolobium roseum vis-a-vis an evaluation of its hypoglycemic activity.

Authors:  Op Gupta; Pavan Malhotra; Surbhi Kudyar; Aneeta Singh; Geetika Gupta
Journal:  Int J Appl Basic Med Res       Date:  2011-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.